225 Promenade du Centropolis
126 articles with Acasti Pharma
Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®Agreement provides Acasti long-term supply of raw krill oil through commercialization
Acasti Pharma Inc. announced that it has partnered with Aker BioMarine to deliver krill oil to Acasti, under a two-year, fixed price supply agreement.
Acasti Pharma (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the pricing of an underwritten public offering of 16,600,000 common shares in the United States at a price to the public of $1.00 per share.
Acasti Pharma Inc. announced today that it intends to offer and sell its common shares in an underwritten public offering in the United States.
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
Acasti Pharma Inc. today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable.
Acasti Pharma today announced its operating and financial results for the quarter ended December 31, 2017, which is the third quarter of Acasti's fiscal year 2018.
Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares
Acasti Pharma announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares (the "Offering") have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000.
Acasti today announced that Neptune's representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti's Board of Directors.
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures
Acasti announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017.
Acasti today announced the granting of a patent by the South Korean Patent Office and the granting of a corresponding patent by the Canadian Intellectual Property Office, further strengthening the international intellectual property position of CaPre.
The Benchmark Company, LLC and Dawson James Securities, Inc. acted as book-running managers for the offering.
Acasti Pharma announced the pricing of its underwritten offering of 9,900,990 common shares together with accompanying warrants to purchase an aggregate of 8,910,891 common shares at a combined price to the public of US$1.01 per share and accompanying warrant.
Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company
The term sheet is preliminary and non-binding at this stage and the license, upfront payment, possible milestone payments, and royalties contemplated by it will only become operative if definitive documents are executed.
If a definitive agreement is reached and signed, the term sheet contemplates that Acasti would receive an upfront payment of $8M upon signing, plus potential additional regulatory and commercial milestone payments in excess of $125M, and tiered double-digit royalties on net sales.
Net loss for the quarter ended September 30, 2017 was $4.5 million or $0.31 loss per share, compared to a net loss of $2.3 million or $0.22 loss per share for the quarter ended August 31, 2016.
Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program
Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3s and lifestyle can influence cardiometabolic health.
Acasti Pharma Granted Additional Composition & Use Patents In Taiwan And Australia; Safeguards Valuable Market Expansion Opportunities
Acasti Pharma Forms Scientific Advisory Board And Appoints Two Leading Cardiovascular Disease Experts
Acasti Pharma Announces Closings Of Concurrent Public Offering Of Units And Private Placement Of Convertible Debentures And Warrants